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Available online 9 February 2017The impact on in vivo efﬁcacy and safety of two novel ionic liquids based on the association of choline with non-
steroidal anti-inﬂammatory drugs, ketoprofen and naproxen forming IL-APIs, was evaluated. Their lipophilicity,
solubility and toxicity were assessed aiming the illustration of the pharmaceutical proﬁle and potential toxic
impact.
Partition coefﬁcientwas determined usingmicelles of hexadecylphosphocholine andUV–Vis derivative spectros-
copy. Additionally, solubility in phosphate buffer pH 7.4 wasmeasured using a modiﬁed shake ﬂask method and
UV–Vis spectroscopy as detection technique. Ultimately, toxicity was considered resorting to a fully automated
cytochrome c oxidase assay based onmicroﬂuidics. The obtained results demonstrated that the IL-APIs' drug for-
mat has the ability to interact with biological membranes and also improves solubility up to 58 times. Moreover,
it was evidenced that, although being a nutrient, choline inﬂuences the IL-APIs' toxicity. The studied anti-inﬂam-
matory IL-APIs exhibited promising properties regarding their incorporation in pharmaceutical formulations.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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The pharmaceutical industry faces nowadays unprecedented chal-
lenges and amendments as a consequence of strong demands related
with economic viability and environmental sustainability. The invest-
ment on research and development is forecast to decline since the
risks associated with drug discovery seem to not be in accordance
with the current economic demands. It is known that 90% of the exper-
imental drugs cannot reach the market mainly due to lack of efﬁcacy,
toxicity and inadequate pharmacokinetics [1,2]. Indeed, approximately
40% of the novel drug candidates fail to obtain approval because of
poor pharmaceutical properties such as reduced solubility or decreased
permeation across the blood-brain barrier [3]. Moreover, the demands
regarding the environmental impact of drug discovery are on the front-
line of the principles of Green Chemistry [4].edients; chol [KTP], choline
x, cytochrome c oxidase; FeC,
; ILs, ionic liquids; IL-APIs,
AP, naproxen; SIA, sequentialTypically, the pharmaceutical industry relies on crystalline forms of
active pharmaceutical ingredients (APIs) with claimed advantages in
terms of purity, thermal stability, manufacturing and handling. Howev-
er, solid APIs often suffer from low solubility and polymorphismconver-
sion, which can have a negative impact on drug bioavailability and
ultimately on its efﬁcacy [2,5]. The issue of efﬁcacy is quite important
considering that this is the most frequent reason for failure in phase II
clinical trials [6]. Salt formation is the most common and cost-effective
strategy to overcome the problems faced by solid forms of APIs, being
estimated that around 50% of all drugs utilized in the pharmaceutical in-
dustry are salts with improved properties regarding the corresponding
ionizable drugs [5,7].
Ionic liquids (ILs) emerged as a new class of compounds with pecu-
liar properties that make them suitable for distinct pharmaceutical ap-
plications [8]. In the past few years, ILs have been explored as reaction
media for the synthesis of APIs [9], as pharmaceutical solvents [10]
and as part of drug delivery systems [11,12]. Additionally, several au-
thors have reported ILs that are themselves the APIs (IL-APIs) [13–17].
From the pharmaceutical point of view, an IL approach in the design
of novel APIs seems to be appropriate as it enables a large number of
possible cation-anion combinationswhile providing singular properties
unreachable in solid salts, namely improved solubility and absence of
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cations and anions empowers the chemicalmanipulation of compounds
with speciﬁc purposes related with the manufacturing process, the sta-
bility of formulations and their bioavailability [18,20]. The research in
this ﬁeld has been focused mostly on the synthesis of new IL-APIs,
their physico-chemical characterization and in vitro assessment of the
expected pharmacological activity [14,17,21]. As far as we know there
are relatively few studies exploring the pharmaceutical properties of
IL-APIs for prediction of their in vivo behavior and there is still little in-
formation regarding the toxicity of these compounds [16,22–26].
Thus, in this work, we studied for the ﬁrst time the lipophilicity, sol-
ubility and toxicity of two anti-inﬂammatory IL-APIs based on choline
(Fig. 1). The selected IL-APIs include distinct anions with well-known
analgesic, anti-inﬂammatory and anti-pyretic activity, namely
ketoprofen (KTP) and naproxen (NAP) [27], combined with the choline
cation, an essential nutrient that is necessary for many critical functions
in the human body [28].
The lipophilicity of the anti-inﬂammatory IL-APIs was assessed
through the calculation of partition coefﬁcient (expressed as log D) by
derivative spectroscopy. The determination was based on the study of
the interaction of the selected IL-APIs with a membrane model aiming
to evaluate the distribution of drugs between aqueous and lipid phases.
It is nowadays accepted and demonstrated that membrane models are
more adequate for this purpose than biphasic solvent systems like
octanol-water since they mimic the lipid bilayer of biological mem-
branes [29,30]. Indeed, biomimetic membrane models are able to con-
sider the hydrophobic, hydrogen bond, dipole-dipole and electrostatic
interactions between drug and membrane, whereas octanol-water sys-
tems can onlymodel nonpolar interactions [31,32]. In the present work,
micelles of hexadecylphosphocholine (HDPC) were used as membrane
model since they are easy and fast to prepare, have high stability and
few spectral interferences, and circumvent the use of toxic organic sol-
vents [33,34].
Taking into account the low solubility of the anions incorporated in
the selected compounds it was evaluated if this property was improved
in the IL format [35,36]. This was performed through the determination
of thermodynamic solubility using the shake ﬂask method. The solubil-
ity issue is of great importance since it is known that solubility affects
both in vitro assay results and in vivo oral bioavailability. Indeed, poor
aqueous solubility is one of the main causes for low systemic exposure
and, consequently, lack of in vivo efﬁcacy [3].
Considering the pharmaceutical potential of IL-APIs, their toxicity
was evaluated resorting to a fully automated cytochrome c oxidase
(CytCox) assay aiming to predict IL-APIs' safety. Enzymatic inhibition
assays have already proved to be useful in clarifying the impact of ILs'
structural elements on toxicity and the way they should be changed to
decrease hazardous potential. The methodology presented the addi-
tional advantage of automation of the assay based on sequential injec-
tion analysis (SIA) as it guarantees a precise control of the reaction
conditions and reduces the consumption of reagents as well as theFig. 1. Chemical structures of the studied IL-APIs: (1) choline ketoprproduction of hazardous efﬂuents, being in good agreement with the
present concerns of Green Chemistry [37,38].
With this work, it is then expected to contribute to the understand-
ing of the potentialities of chol [KTP] and chol [NAP] to replace their APIs
counterparts. For that, these compounds were submitted to new assays
to evaluate more pharmaceutical properties and toxicity in order to
complement the information gathered during their synthesis and
physico-chemical characterization as well as their binding afﬁnity data
[26]. The comparison of the IL-APIs' proﬁle with the respective starting
materials aims to highlight some of the features of APIs in the IL format.
Moreover, by contributing to the revealing of the drug-like nature of
these compounds it is also expected to give early warning of potential
difﬁculties in formulation, process development and safety that would
otherwise increase development time/cost and delay their possible clin-
ical introduction.
2. Experimental
2.1. Chemicals
All solutions were prepared using chemicals of analytical reagent
grade and high purity water (Milli-Q water) with a speciﬁc
conductance b 0.1 μS cm−1.
KTP (2-(3-Benzoylphenyl)propionic acid), Na [NAP] ((S)-6-
Methoxy-α-methyl-2-naphthaleneacetic acid sodium salt), Tris (2-
Amino-2-(hydroxymethyl)-1,3-propanediol), CytCox from bovine
heart (EC 1.9.3.1), cytochrome c and DL-dithiothreitol (threo-1,4-
Dimercapto-2,3-butanediol) were all purchased from Sigma-Aldrich
and used as supplied. HDPC was obtained from Cayman Chemical and
used without further puriﬁcation. chol [KTP] and chol [NAP] (99%)
were synthesized and characterized as reported in our previous work
[26]. The tested IL-APIs were stored at room temperature in a carefully
controlled anhydrous environment.
The partition coefﬁcient and solubility assays were performed in
phosphate buffer 0.1 mol L−1, pH 7.4 (I = 0.15 mol L−1). A stock sus-
pension of HDPC 600 μmol L−1 was prepared daily in the described
phosphate buffer solution and a suspension of HDPC 150 μmol L−1
was prepared by suitable dilution of the stock suspension in the same
buffer. In the toxicological assays, a Tris-HCl buffer 0.01 mol L−1
(pH 7.0), containing KCl 0.12 mol L−1 was used as carrier in the ﬂow
system. CytCox 0.2 U mL−1 was reconstituted in Tris-HCl enzyme dilu-
tion buffer 0.01mol L−1 (pH 7.0), with sucrose 0.25mol L−1, and divid-
ed in 12 working solutions, which were stored at−20 °C. Each aliquot
of working solution was reconstituted with enzyme dilution buffer at
a ﬁnal concentration of 0.01 U mL−1. Ferrocytochrome c (FeC) solution
was prepared daily by the combination of 25 μL of DL-dithiothreitol
0.1 mol L−1 solution, previously prepared, 13.5 mg of cytochrome c
and water to a ﬁnal volume of 5 mL.
In the partition coefﬁcient assays solutions of chol [KTP] and KTP
250 μmol L−1, chol [NAP] and Na [NAP] 800 μmol L−1 were preparedofenate (chol [KTP]) and (2) choline naproxenate (chol [NAP]).
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IL-APIs and respective starting materials were prepared in the same
buffer, in increasing concentrations.
2.2. Instrumentation
In the batch assays, absorbancemeasurements were performed on a
Synergy HT Multi-Mode (BioTek Instruments) microplate reader.
In the solubility studies a C-MAG HS 7 magnetic stirrer (IKA) was
used to mix the aqueous and solid phases. The samples were centri-
fuged using an Allegra X-15R centrifuge (Beckman Coulter).
The toxicity of IL-APIs and corresponding starting materials to
CytCoxwas evaluated in a fully automated SIA system (Fig. 2) previous-
ly reported [39]. Spectophotometric measurements were performed
resorting to a 6300 Jenway spectrophotometer model set at 550 nm
and equipped with a 18 μL ﬂow cell (Helma 178.711QS, Mülheim,
Balden, Germany). A syringe module Bu1S from Crison Instruments
S.A. (Allela, Barcelona, Spain) and a 10-port multiposition Cheminert™
selection valve were controlled by computer. A glass syringe of 5 mL
total dispense volume (Hamilton Bonaduz AG, Switzerland) was
coupled to the syringe equipment and driven by a stepper motor. Sole-
noid head-valves allowed the commutation of the syringe either to the
manifold or to the carrier. All the componentswere connected bymeans
of 0.8 mm i.d. PTFE tubing, which was also used for the holding and re-
action coil (2 and 1 m, respectively). The data acquisition was recorded
in a strip chart recorder (Kipp&Zonen BD 111) or via computer.
2.3. Assessment of partition coefﬁcient by derivative spectroscopy
The study of the partitioning of the selected IL-APIs and correspond-
ing starting materials between the aqueous and lipid (HDPC) phases
was performed by derivative spectroscopy through a microplate assay
described byMagalhaes and co-workers [34]. Buffered solution contain-
ing a ﬁxed drug concentration (chol [KTP] and KTP 250 μmol L−1, chol
[NAP] and Na [NAP] 800 μmol L−1) was added to increasing concentra-
tions of HDPC ranging from 7.5 to 200 μmol L−1. The corresponding ref-
erence suspensions were identically prepared in the absence of drug.
The absorption spectra of samples and references were recorded at
37 °C in a microplate reader in accordance with the abovementioned
protocol, in the range of 200–500 nm [34].
The mathematical treatment of the experimental data was per-
formed using the Excel routine Kp calculator [34]. Brieﬂy, this spread-
sheet tool subtracts each reference spectrum from the respective
sample spectrum to obtain corrected absorption spectra and subse-
quently determines the ﬁrst, second and third derivative spectra. Deriv-
atization allows the elimination of spectral interferences resulting fromFig. 2. Schematic representation of the SIA manifold. B: Tris-HCl buffer, 0.01 mol L−1
(pH 7.0), containing KCl 0.12 mol L−1; S: syringe; HC: holding coil; SV: selection valve;
RC: reaction coil; SP: spectrophotometer; W: waste; IL-API/API: chol [KTP] or KTP, chol
[NAP] or Na [NAP]; CytCox: cytochrome c oxidase; FeC: ferrocytochrome c.light scattered by the lipid micelles, enhance the ability to detect minor
spectral features and improves the resolution of bands [33,40]. After
this, the partition coefﬁcients were calculated by ﬁtting the following
equation to the experimental data (Dt vs. [L]) using a non-linear least-
squares regression method [34]:
Dt ¼ Dw Dl−Dwð ÞKp L½ 1þ Kp L½  ð1Þ
whereD is the derivative intensity obtained from the absorbance values
of: total amount of drug (Dt); drug distributed in the lipid (Dl) and in the
aqueous (Dw) phase, respectively; [L] HDPC concentration (mol L−1)
and Kp is the partition coefﬁcient expressed asmol L−1. The dimension-
less value was calculated from the division of the molar partition coefﬁ-
cient by the HDPC molar volume.
2.4. Determination of solubility by a shake ﬂask method
The thermodynamic solubility of the synthesized IL-APIs and respec-
tive startingmaterials in phosphate buffer pH 7.4was determined using
a modiﬁed shake ﬂask method. Samples were prepared by adding an
excess amount of each drug to 1.5 mL of the buffer in screw cap vials.
The vial contents were then mixed with a magnetic stirrer at 500 rpm
for 8 h, allowing time for the system to reach equilibrium between the
dissolved and solid compound. Afterwards, the saturated solution was
separated from the precipitate by centrifugation at 10,000 rpm for
30 min. The resulting supernatant was appropriately diluted in phos-
phate buffer and the concentration of drug was measured spectropho-
tometrically in a microplate reader at the wavelength of maximum
absorbance. For each drug, calibration curves were previously
established using standard solutions of different concentrations of the
drug in phosphate buffer. All the experiments were carried out in tripli-
cate at 37 °C.
2.5. Evaluation of toxicity through automated CytCox assay
CytCox activity in the presence and in the absence of IL-APIs and cor-
responding starting materials was determined according to the analyt-
ical cycle optimized for that purpose [39]. The assays were performed
at room temperature.
The real concentration of inhibitor in the ﬂow systemwas calculated
through the application of an experimentally determined dispersion
factor correction. The results of the inhibition assays were presented
as normalized CytCox activity, corresponding the maximum value 1 to
CytCox activity in the absence of inhibitor. The effective concentration
of the compound causing a decrease of 50% of enzyme activity was de-
termined and represented as IC50 value. The calculations were per-
formed by means of linear or polynomial correlations established in
the inhibition assays for each tested compound.
3. Results and discussion
3.1. Partition coefﬁcient of anti-inﬂammatory IL-APIs
In thiswork, the lipophilicity of the synthesized IL-APIswas assessed
through the determination of partition coefﬁcients of drugs between
aqueous and lipid phases. With this we intended to collect data that
can be useful for the prediction and understanding of the passive diffu-
sion processes of drugs across biomembranes. Considering the ionic na-
ture of IL-APIs and the zwitterionic lipids as themajor lipid components
of eukaryotic membranes we resorted to neutral micelles of HDPC that
enable the establishment of interactionswith either lipophilic or hydro-
philic drugs, contrary to other models like octanol-water [33].
The log D values of the tested IL-APIs and respective starting mate-
rials are listed in Table 1. As an example, the plot of the absorbance
Table 1
Partition coefﬁcients (log D) (dimensionless) of IL-APIs and respective
starting materials in micelles of HDPC at physiological conditions (pH
7.4 and 37 °C).
Compound log D± SDa
IL-APIs chol [KTP] 5.44 ± 0.03
chol [NAP] 5.44 ± 0.03
Starting materials KTP 5.48 ± 0.02
Na [NAP] 5.47 ± 0.02
a The values presented are the mean and the standard deviation of 3
replicates.
23A.M.O. Azevedo et al. / Journal of Molecular Liquids 232 (2017) 20–26values and the 1st and 2nd derivative graphs for chol [KTP] at different
micellar concentrations are presented in Fig. 3.
The similarity between the logD values of IL-APIs and corresponding
starting materials indicated that the utilization of KTP and NAP in the IL
format does not alter the ability to permeate biological membranes. The
same trend was observed by Florindo and co-workers for a series of ILs
based on ciproﬂoxacin and norﬂoxacin [24]. Moreover, Kawai et al. re-
ported that choline based ILs can penetrate through cell membranes be-
cause their molecular structures resemble choline, which is transported
across membranes for use as a precursor in the synthesis of acetylcho-
line and phospholipids [41].
KTP and NAP are weak acidic drugs that possess a carboxylic group
that can undergo deprotonation (pKa = 3.88 and 4.19, respectively).
At the physiological pH (pH = 7.4) almost 100% of drug molecules are
negatively charged, according to calculations made in Marvin SketchFig. 3. Absorbance (A), 1st (B) and 2nd (C) derivative data at 258, 274 and 288Calculator software fromChemAxon. The octanol-water distribution co-
efﬁcients (log D) predicted byMarvin Sketch at pH 7.4 for KTP and NAP
were 0.39 and−0.05, respectively. The discrepancy between experi-
mental and calculated log D values can be explained by the fact of soft-
ware does not take into account the ionic interactions established
between the charged drugs and the polar head groups of the phospho-
lipids of membranes. These observations highlight the advantage of
using membrane models for the determination of partition coefﬁcients
since hydrophobic forces are not the only interactions driving the
drugs partition, which also encodes electrostatic interactions.
3.2. Solubility of anti-inﬂammatory IL-APIs in phosphate buffer pH 7.4
The study of the solubility of the selected IL-APIs was conducted in
phosphate buffer pH 7.4 with the objective of further elucidate the ab-
sorption of these compounds. This issue is of utmost importance since
it is known that poorlywater-soluble drugs tend to have incomplete ab-
sorption and subsequently low bioavailability. Thus, the thermodynam-
ic solubility was measured by a modiﬁed shake ﬂask method, ensuring
that the equilibrium between the dissolved and solid drug was reached
[42].
The comparison of the solubility at 37 °C of IL-APIs with the corre-
sponding starting materials is depicted in Fig. 4.
As can be seen, both IL-APIs display greater solubility in phosphate
buffer pH 7.4. chol [KTP] was 58 times more soluble than KTP and for
chol [NAP], even when compared with Na [NAP], it was observed a 4-
fold increase of its solubility. The observed differences can be relatednm, respectively, for chol [KTP] at different HDPC micellar concentrations.
Fig. 4. Solubility of the synthesized anti-inﬂammatory IL-APIs and corresponding starting
materials in phosphate buffer solution pH 7.4 at 37 °C.
Fig. 5. Experimental toxicity data of the tested IL-APIs and respective starting materials in
CytCox assay.
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and that the salt formation is oneof themost frequently employed strat-
egies to improve solubility and, ultimately, bioavailability of poorly
water-soluble drugs [7,43]. Murti et al. demonstrated that chol [NAP]
was 2 times more soluble than Na [NAP] [44]. However, the discrepan-
cies between those and our results could be explained by the different
temperature used (25 and 37 °C, respectively). Two other studies re-
ported an increased solubility of IL-APIs containing the choline cation
compared to the parent APIs [22,45]. Similar observations were made
by Florindo and co-workers for IL-APIs based on ﬂuoroquinolone
drugs [24].
Moreover, from the analysis of the solubility values obtained for chol
[NAP] and Na [NAP] it was possible to conclude that the selection of the
most appropriate counter-cation enables the ﬁne-tuning of the solubil-
ity of API. The higher solubility of chol [NAP] can be explained by the
presence of the hydroxyl group in the alkyl chain of choline, which en-
hances the polarity and the hydrogen bonding capacity of the
compound.
3.3. Toxicity of anti-inﬂammatory IL-APIs towards CytCox
Choline is a quaternary ammonium compound with vast industrial
potential, considering the general idea of environmentally benign struc-
ture [46,47] and its role in the organism, from cellmembranes to cholin-
ergic neurotransmission [28]. Therefore, an increase number of new ILs
incorporating the choline cation have been described [48–50]. Con-
versely, there is little information about the biodegradability and toxic-
ity proﬁle of these compounds.
The evaluation of chemicals' toxicity by means of enzyme inhibition
presents advantages such as simplicity of laboratory implementation
and data interpretation, reduction of costs and duration of the assays.
In this section, we report the toxicity of new synthesized choline
based IL-APIs through the inhibition of CytCox activity on a SIA system.
The inhibition proﬁles of the tested compounds are shown in Fig. 5
and the respective IC50 values are presented in Table 2. Due to solubility
problems, it was not possible to determine the IC50 value of KTP.
Comparing the anions of chol [KTP] (IC50 = 21.32 mmol L−1) and
chol [NAP] (IC50 = 0.47 mmol L−1), which confer the pharmacological
activity to respective compounds, it was veriﬁed a higher toxic effect
for the naproxen anion. The anions have a similar composition with
slight differences in the arrangement of the two aromatic rings and
the oxygen atom. It appears that naphthalene and terminal methoxy
groups have a greater negative effect on enzyme activity than two phe-
nyl groups linked by a ketone function. The higher IC50 value of chol
[KTP] could be related to an easier degradation of the molecule at the
ketone group. Additional studies are needed to conﬁrm the hypothesis
or identify other factors that might be involved in the toxicological
mechanism. There is few information about NAP and KTP (eco)toxicitystudies, especially with CytCox, to enable a reliable comparisonwith lit-
erature data. Farré et al. [51] studied the toxic effect of some drugs on
the aquatic organism Vibrio ﬁscheri and observed similar EC50 values
for NAP and KTP, being the last one slightly more toxic. The results ob-
tained for Na [NAP] (IC50 = 5.91 mmol L−1) and chol [NAP] (IC50 =
0.47mmol L−1) demonstrated that the IL-API ismore toxic than the cor-
responding starting material. The decrease of the IC50 value could also
be related with solubility increase, which may contribute for its bio-
availability enhancement. This in turn may explain the increase in
CytCox activity inhibition. A similar inhibition trend was reported by
our group for salicylate derived IL-APIs [23]. Despite the choline cation
presented higher toxicity than sodium, the IC50 differences are small
considering that sodium is a recognized inert ion, i.e., it not contributes
signiﬁcantly to themolecule toxicity. Indeed,most of theworks describe
choline as a relatively safe compound due to its structure, i.e., a quater-
nary ammonium cation incorporating a polar hydroxyl group in one of
its alkyl side chains [48,52]. However, some studies have revealed that
choline based ILs are not always harmless [49,53]. Santos et al., for ex-
ample, observed that six of the ten tested ILs have hazardous potential
[53]. The researchers also highlight the importance of the anion on ILs'
toxicity, as demonstrated by our results for the tested IL-APIs. On the
other hand, the higher IC50 values of the synthesized IL-APIs (up to 93
times) compared to zinc ion (IC50 = 230 μmol L−1), a recognized
CytCox inhibitor, suggest that these compounds are not strong inhibi-
tors of enzyme activity [54]. Cooper and co-workers also reported
lower IC50 values (in the nanomolar range) for nitric oxide than those
obtained in the present work for chol [KTP] and chol [NAP] [55].4. Conclusions
In this work, we studied the lipophilicity, solubility and toxicity of
two anti-inﬂammatory choline based ILs with the aim of further eluci-
date their pharmaceutical proﬁle and potential toxic effects.
The obtained results demonstrate the potential of the IL platform in
the design of new APIs since the synthesized compounds not only show
ability to interact with biological membranes but also present improved
solubility. This can have a positive impact on drug bioavailability and ul-
timately on its efﬁcacy. Moreover, the observed toxic alterations con-
ﬁrm the inﬂuence of IL-APIs' structural elements, namely the cation
and anion, on their toxicity.
Still, further studies could be performed in order to conﬁrm either
the therapeutic effect or toxicity of the synthesized IL-APIs on humans.Acknowledgments
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